Field PULSE Trial 12-Month Outcomes Published in JACC: Clinical Electrophysiology

Field Medical, Inc. has published 12-month outcomes from its first-in-human Field PULSE trial, evaluating high-voltage focal PFA with the FieldForce™ PFA System. The study assessed the durability of ablation procedures.

The results, featured in JACC: Clinical Electrophysiology, demonstrated 94.2% per-vein PVI durability following ablation. These findings advance Field Medical's "instantaneous ablation" workflow and expand clinical evidence for their PFA system.

Field Medical states that the data provide further support for the clinical utility of high-voltage focal PFA in treating cardiac arrhythmias. The company aims to improve and streamline cardiological interventions through technological advancements.